GlaxoSmithKline Do more, feel better, live longer

What's New?

November 10, 2011

November 02, 2011

October 20, 2011

---

At GSK, we put your leadership skills to work in a way that maximizes your full potential as a person.

 

 

Research & Development

GlaxoSmithKline is one of the largest research and development (R&D) investors in the industry, collaborating with academic institutions, governments and other pharmaceutical and biotechnology companies to help people live healthier lives.

Globally, the company spends 6.5 billion every year on R&D.

---

GSK Canada Life Sciences Innovation Fund

On November 10, 2011, Paul Lucas, President and CEO, GlaxoSmithKline Inc. (GSK), together with Dr. Moncef Slaoui, Global Chairman of Research and Development at GlaxoSmithKline plc. announced the launch of a new $50M GSK Canada Life Sciences Innovation Fund. This fund will significantly benefit Canada’s life sciences community by supporting early stage breakthrough science and accelerating the commercialization of Canadian innovations through investment in Canadian academic and health research institutions, translational research centres and start-up companies

---

GSK’s commitment to operating with transparency in Canada

As a proud member of Canada’s Research Based Pharmaceutical Companies (Rx&D), GSK is committed to operating with transparency and to building trust in Canada. We believe in the value of building strong, effective stakeholder relationships and have undertaken several initiatives to demonstrate our commitment to transparency.

GlaxoSmithKline:
A global leader in dermatology

Stiefel, a GSK company, is a world-leading specialist dermatology business with the innovative products that are highly regarded for quality and effectiveness and have the respect and trust of healthcare professionals and their patients.

Stiefel, a GSK company, has access to some of the best R&D capabilities in the world, allowing for the advancement of their dermatology pipeline and delivery technologies at an even greater speed and the ability to bring even more novel therapies to market.

100% focused on HIV - Patient Centric - Committed to innovation

Established by GlaxoSmithKline and Pfizer, ViiV Healthcare is a specialist HIV company with a sustainable commitment to delivering advanced treatment and care, and improving access to medicines for people living with HIV worldwide.